172 results on '"Badimon, Juan Jose"'
Search Results
2. Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens
3. Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction
4. Los iSGLT2 en la insuficiencia cardiaca. ¿Sus beneficios pueden extenderse a todo el espectro de la fracción de eyección?
5. Not only how much, but also how to, when measuring epicardial adipose tissue
6. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study
7. Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
8. ¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares?
9. Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity
10. Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts
11. Inhibición dual del SGLT1 y SGLT2: algo más que su suma
12. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?
13. Antithrombotic and Prohemorrhagic Actions of Different Concentrations of Apixaban in Patients Exposed to Single and Dual Antiplatelet Regimens
14. From Vulnerable Plaque to Vulnerable Patient – Part III : The SHAPE Paradigm – Screening for Detection and Treatment of Asymptomatic Atherosclerosis, Task Force Report, Executive Summary
15. Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood
16. HDL: un nuevo biomarcador para la insuficiencia cardiaca
17. Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial
18. Coronary Artery Disease in Aging Women: A Menopause of Endothelial Progenitor Cells?
19. Changes in Vascular Geometry in Atherosclerotic Plaque Rupture and Its Relationship to Thrombosis in Acute Vascular Events
20. Incremento de las HDL como arma terapéutica en la aterotrombosis
21. Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease
22. Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?
23. Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?
24. Effects of electret coating technology on coronary stent thrombogenicity
25. Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis
26. Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood
27. From Vulnerable Plaque to Vulnerable Patient – Part III
28. Effects of electret coating technology on coronary stent thrombogenicity.
29. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
30. Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection
31. Pathophysiology of arterial thrombosis
32. The vulnerable plaque and acute coronary syndromes
33. Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease
34. Rapamycin Inhibits Vascular Smooth Muscle Cell Migration
35. Antithrombotic effects of Abciximab
36. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
37. Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis
38. Effect of High-Density Lipoproteins on Experimental Atherosclerosis
39. Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?
40. Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation
41. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality
42. High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities
43. Reply
44. DIFFUSE INTERSTITIAL MYOCARDIAL FIBROSIS DETECTED BY T1 MAPPING IS INCREASED IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS AND CORRELATES WITH LEFT VENTRICULAR SYSTOLIC AND DIASTOLIC DYSFUNCTION
45. CINE BALANCED STEADY-STATE FREE PRECESSION IS A RELIABLE ALTERNATIVE TO CONVENTIONAL T2-WEIGHTED IMAGING AND EVANS BLUE FOR THE CMR ASSESSMENT OF AREA AT RISK AFTER MYOCARDIAL INFARCTION
46. Abstract 17034: The Novel Extracellular Matrix Protein Podocan Shows a Distinct Expression Pattern in Human Primary versus Restenotic Atherosclerotic Coronary Lesions and its Lack of Extra-Cellular Expression in Restenotic Tissue is Associated with Increased Wnt-Pathway Activation
47. Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?
48. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery☆☆☆
49. RECOMBINANT APOLIPOPROTEIN A-I MILANO DECREASES LEAFLET INFLAMMATION AND CALCIFICATION IN EXPERIMENTAL MODELS OF AORTIC STENOSIS
50. From Vulnerable Plaque to Vulnerable Patient
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.